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Abstract
Background: To investigate the costs of treatment with basal insulin (insulin NPH [NPH], insulin glargine [IG],
insulin determir [IG]), and premixed insulin (PM) in routine clinical care.
Methods: Cohort study based on data from the Swedish National Diabetes Register, including 5077 insulin-naïve
men and women with type 2 diabetes, resident in a distinct geographical region of Sweden. Patients were
included between 1 July 2006 and 31 December 2009 and followed for 12 months. All drug- and healthcare-
related costs, stratified by diabetes-related or non-diabetes care contacts, were quantified and compared to
baseline.
Results: Initiation of insulin treatment generally entails increased diabetes-related health care contacts and
treatment costs, and decrease in health care costs. The median changes in costs were generally smaller than the
mean changes, reflecting great variations between patients. The treatment costs were higher for IG, ID and PM
compared with NPH, although higher age, history cardiovascular disease and diabetes complications as well as
higher diabetes-related and other treatment costs were independent predictors. Overall, only PM (but not IG or
ID) were associated with higher diabetes-related health care costs, although these were also independently
predicted by cardiovascular morbidity and markers of complicated diabetes.
Conclusions: This study demonstrates that the initiation of insulin in patients with type 2 diabetes in clinical
practice leads to increased health care contacts, overall and treatment costs, but also generally results in a
decrease in health care costs. The diabetes-related treatment cost was lowest using NPH insulin but only
premixed insulin was associated with higher diabetes-related health care costs than NPH.
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Background
Insulin treatment is commonly used in patients with type
2 diabetes when lifestyle changes and oral hypoglycemic
agents (OHA) fail to achieve adequate glycemic control
[1, 2]. The medium long-acting NPH (neutral protamine
Hagedorn) given at bedtime has been a common first-
hand choice, but a long-acting insulin analogue (insulin
glargine (IG) or insulin detemir (ID)) is frequently
used, particularly in patients experiencing nocturnal
hypoglycaemia. Pre-mixed insulin (PM), usually ad-
ministered twice daily, is another useful treatment
option [3].
The clinical effects of these treatment alternatives have
been evaluated in randomized clinical trials (RCT) and
meta-analyses, and recently also in clinical practice [4, 5].
Overall there are no major differences in the effects on
glycemic control, but there can be differences in weight
effects, hypoglycemia and insulin doses as well as in
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persistence. We recently studied the clinical effects in
5077 insulin-naïve type 2 diabetes patients in a geograph-
ically distinct region of Sweden (Region Västra Götaland),
who initiated treatment on NPH, IG, ID or PM [6]. The
different insulin regimens were found to be equally effect-
ive in lowering HbA1c, but PM required 59 % higher and
ID 25 % higher insulin doses to achieve a similar HbA1c
reduction as NPH. PM was also associated with a signifi-
cantly greater increase in BMI compared with NPH, and a
small but higher number of patients experiencing severe
hypoglycemia than the other treatment groups.
The high costs associated with diabetes care have long
been recognized, but the number of published studies in
this area is low. A recent report based on managed care
administrative data in the U.S.A. described in detail the
total health care costs for patients with type 2 diabetes [7].
The strongest predictors of high costs for the patients were
obesity, comorbidities and hospitalization, but also progres-
sion to insulin therapy. There are also very few studies
addressing the total costs associated with different insulin
regimens, although development programs (RCTs) for new
pharmaceutical agents also often include health economic
analyses [8]. In clinical practice, the addition of IG, com-
pared with PM, to treatment with oral hypoglycemic agents
(OHA) was recently examined, showing better persistence
and lower costs [9].
There are no studies available comparing costs of dif-
ferent insulin regimens when added to OHA in unse-
lected cohorts in clinical practice. The aim of this study
was therefore to examine health care utilization and
costs in our recent study with 5,077 insulin-naïve type 2
diabetes patients, after starting treatment with NPH, IG,
ID or PM [6].
Methods
The overall design of this study has recently been described
in detail [6]. To summarize, we linked data from four
national health registers: the Swedish National Diabetes
Register (NDR; clinical data), the Prescribed Drug Register
(pharmacological agents, doses), the Cause of Death Regis-
ter, and the Regional Claims Database (VEGA). The latter
contains diagnoses (International Classification of Diseases
[ICD]-10 and Diagnosis Related Groups [DRG] codes), pro-
cedures performed (Nordic Medico-Statistical Committee
[NOMESCO] and local procedure codes) and hospital
lengths of stay for inpatient, outpatient, primary, and pri-
vate care for all inhabitants in the Region Västra Götaland.
Ethics, consent and permissions
All included patients have agreed by informed consent to
be registered before inclusion. The Ethics Review Board at
the University of Gothenburg approved the study.
Patients, study period, follow-up and censoring
We included insulin-naïve patients with type 2 diabetes, at
least 18 years of age. The study period was between 1 July
2005 and 31 December 2010. Patients were not allowed to
fill a prescription of insulin from 1 July 2005 to 30 June
2006 to ensure they were previously untreated (data from
the Prescribed Drug Register). Patients were required to
have their first prescription of insulin filled (index date)
between 1 July 2006 and 31 December 2009 to allow for
1 year of follow-up. Patients were thus followed for
12 months or until the occurrence of a censoring event.
The mean number days of follow-up were similar in the
four treatment groups (352 ± 47 NPH, 358 ± 37 IG, 351 ±
51 ID and 352 ± 47 PM) [6]. Start of follow-up was
defined as the date of the first filled insulin prescription
(index date) in each patient. In order to ensure con-
tinuous insulin use, at least three filled prescriptions of
the initiated insulin were required during the follow-up
period. Censoring events included a filled prescription
of a new type of insulin, death or move out of the
Region Västra Götaland.
Costs
Treatment costs (drug-related costs) were retrieved from
the Prescribed Drug Register, which has full, nation-wide
coverage of all transactions that are made at pharmacies
in Sweden, including all drugs (ATC codes A-V) and
technical aids (ATC codes W-Y). We used data between
2005-07-01 and 2010-12-31.
Healthcare costs were estimated by using the associ-
ated DRG-codes (data from VEGA). To make data com-
parable, Swedish national DRG-weight lists and costs for
2010 were used (National Board of Health and Welfare,
http://www.socialstyrelsen.se/english). VEGA also pro-
vided data on outlier costs, which were considered when
estimating the final cost per care contact. For outdated
DRG-codes, old DRG-weight lists provided by the Swedish
National Board of Health and Welfare were used to extract
weights, which were used in combination with the 2010
DRG cost. Further, psychiatric DRG-codes were flagged,
and the clinic setting where the care contacts occurred,
were used to determine whether DRG-weights from the
inpatient DRG-list or the psychiatric DRG-list should be
applied. For primary care, costs were determined based on
the caregiver, where physicians were assumed to have a
three times higher rate than other caregivers (e.g. nurses,
physiotherapists, etc.). This corresponded to a 1840 SEK
cost for a physicians visit, and a 615 SEK cost for all other
primary care visits. The approximate value of 100 SEK is
currently 12 US dollars (August 2015).
We studied all drug- and health care-related costs, strati-
fied by diabetes-related or non-diabetes care contacts. All
costs 12 months before initiation and during follow-up of
insulin treatment were recorded. A correlation analysis with
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costs before and after insulin treatment initiation was
performed, to determine whether incremental analysis or
pre-index cost adjustment should be undertaken. If the cor-
relation exceeded 0.5, an incremental analysis whereby the
prior (baseline) costs are subtracted from the costs ob-
served during follow-up, was recommended. Otherwise,
the pre-index costs were included as a covariate in the
regression model. Costs are presented in 2010 SEK value
after adjusting for consumer price indices provided by
Statistics Sweden (www.scb.se/en).
Costs were stratified by whether they were diabetes-
related or not, in a mutually exclusive manner, including
anti-diabetic treatment costs as well as costs of cardio-
vascular risk factor treatments (antihypertensive and
lipid-lowering treatment, platelet aggregation inhibitors).
We also identified all diabetes-related care contacts and
their associated costs through the ICD-10 codes E11*,
E13*, and E14* (regardless of diagnosis position), as well
as cardiovascular disease costs, such as myocardial in-
farction/ischaemic heart disease (I20-I25), atrial fibrilla-
tion (I48), congestive heart failure (I50*), and stroke
(I61, I63, I64, I67.9).
Statistical methods
Baseline characteristics are presented as means ± 1 stand-
ard deviation (SD) or medians for continuous variables
and frequencies for categorical variables with crude sig-
nificance levels for differences between the groups, when
analysed using ANOVA or χ2 test. For continuous vari-
ables with non-normal distribution a Kruskal-Wallis test
was performed. All continuous outcome variables were
explored for their distribution.
We used generalized linear modeling (GLM) after log
transformation to assess potential predictors of diabetes-
related health care contacts, health care costs and treat-
ment costs. For each outcome, three models were ex-
plored and presented; firstly, unadjusted where outcome
was as a function of insulin groups, secondly, including
covariates with few missing values (age, gender, level of
income, diabetes duration, history of CVD, history of
diabetes complications, previous OHA use, and follow-
up time), and finally a fully adjusted model including
age, gender, level of income, diabetes duration, history of
CVD, history of diabetes complications, previous OHA
use, follow-up time, pre-index HbA1c, pre-index BMI
and weight. Pre-index diabetes-related costs were in-
cluded as a covariate to account for the patient’s type 2
diabetes history and severity. Further, post-index other
costs (including cardiovascular costs) were included in
the model as a covariate to account for the overall
disease burden (comorbidities) of the population, which
in turn might affect post-index diabetes-related costs.
Statistical analyses were performed in R (R Foundation
for Statistical Computing) or SAS V.9.3 (SAS Institute,
Cary, North Carolina, USA). A two-sided p value <0.05
was considered statistically significant.
Results
As previously reported, 5077 insulin-naïve patients with
type 2 diabetes were included in the study [6]. The pa-
tients were mostly initiated on NPH (49 %) or PM
(34 %), while 13 % and 3 % were initiated on IG and ID.
To summarize, there were modest but significant reduc-
tions in glycemic control (HbA1c) for patients treated
with NPH, IG, ID or PM during one year of follow-up,
but the effects of the different regimens did not differ.
The weight-adjusted daily insulin doses with ID and
PM were 59 % and 25 % higher to achieve similar
HbA1c when compared with patients treated with
NPH, while the patients treated with PM gained more
weight compared with patients treated with other insu-
lin regimens. The recorded number of patients experi-
encing a hypoglycaemic event was low (only 26 patients
in total), but occurred predominantly in patients
treated with PM. The mean number of days of follow-
up was highest in patients initiating IG.
The numbers of visits in health care before and after
starting the insulin treatment are given in Table 1. There
was an increase in the number of visits for all four ana-
lyzed insulin regimens during the follow-up period. For
diabetes-related visits, small differences in the mean
number of visits during the pre-index period were ob-
served, such that IG and PM patients had slightly more
visits. During the follow-up period, NPH patients had the
highest mean number of diabetes-related health care con-
tacts, while ID had the lowest. When diabetes-related care
contacts including cardiovascular comorbidities were
evaluated, PM had the highest mean number of contacts
during the pre-index period, while during the follow-up
period, IG, PM, and NPH patients all had close to three
contacts. For other care contacts, PM and IG patients had
the highest frequency during both the pre-index and the
post-index period. For the patients who did have a
change in number of contacts (N = 4239), there was no
significant difference between the different treatment
groups (Additional file 1: Table S1). Adjusting for several
covariates emphasized this result, although lower age and
use of OHA were independent predictors of less health
care contacts. A history of cardiovascular disease, diabetes
complications, higher pre-index diabetes-related and other
health care costs were independent predictors of more
health care contacts.
The costs of health care and treatments before and
after starting the insulin treatment are given in Table 2.
Diabetes-related costs varied substantially between the
treatment groups for all pre-index and post-index treat-
ment and health care costs. The mean pre-index health
care costs were considerably higher in the PM patients
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at (SEK 30 990), compared with SEK 22 861 and SEK 19
674 for IG and NPH groups, and SEK 9544 for ID,
reflecting differences in clinical characteristics. The
mean pre-index treatment costs were around 50 %
higher for IG and ID compared with PM and NPH. The
health care costs during follow-up were lower for all
groups but the ID group, with a similar magnitude of
decrease for IG and NPH, while the PM showed the lar-
gest decrease. Post-index diabetes-related treatment
costs were higher for all groups, compared to pre-index
treatment costs, in line with the expectations of a more
intense treatment regime after insulin initiation. As ex-
pected, the IG and ID still had higher treatment costs, while
the proportional cost increase compared to PM and NPH
was smaller for IG, at 30 %, compared to 50 % for ID.
For diabetes-related costs where also cardiovascular
costs were included (Table 3), similar patterns as for
diabetes-related costs were observed. The main differ-
ences were that pre-index treatment costs were more
similar between groups when CVD treatment was taken
into account, and that all treatment groups showed cost
decreases when comparing pre- and post-index health
care costs.
The median costs for both health care and treatment in
both Tables 2 and 3 were consistently lower than the mean
costs, reflecting an asymmetrical cost distribution among
the patients with a few patients with very high costs. The
discrepancies between the median and the mean costs
were more pronounced in the health care costs than the
treatment costs. The median increment health care cost
was 0 for NPH, IG and ID. For PM there was a small dec-
rement in median health care costs.
For other pre-index health care costs (Table 4), the
PM patients consistently showed highest mean costs and
ID patients lower costs, and this pattern was repeated
also for pre-index treatment costs. For post-index costs,
the IG and PM groups showed the highest mean costs,
which were also seen for post-index treatment costs
(p < 0.01). Overall, the differences in incremental other
costs between insulin groups were non-significant,
while the patterns indicated a moderate increase for
treatment costs for all groups.
For patients who did have a change in diabetes-related
health care costs (N = 4232), IG and PM increased costs
compared with NPH, whereas ID lowered costs in an
unadjusted model (Additional file 1: Table S2). In the
fully adjusted model only PM was associated with in-
creased health care costs compared with NPH, but
higher age, a history of cardiovascular disease, diabetes
complications, and pre-index diabetes-related and other
health care costs independently predicted higher costs,
while previous use of OHA predicted lower diabetes-
related health care costs. There were higher treatment
costs with IG, ID and PM compared with NPH (Additional
file 1: Table S3). ID increased treatment costs more than IG
and PM in relation to NPH in both the unadjusted and the
adjusted models. In the latter model, higher age, a history
of cardiovascular disease, diabetes complications, use of
OHA, were independent predictors of lower, while higher
municipality income as well as pre-index diabetes-related
and other health care costs predicted higher diabetes-
related treatment costs.
Table 1 Number of contacts with the health-care before and















































p-values 0.003 0.044 0.00004 0.022 0.00002 0.0009
NPH Neutral protamine Hagedorn, IG insulin glargine, ID insulin determir,
PM premixed insulin, SD standard deviation
Table 2 Costs (SEK) of health care and treatments before and after starting the insulin treatment
Pre-index Post-index Increment Net cost
effectHealth care Treatment Health care Treatment Health care Treatment
Treatment Mean/Median Mean/Median Mean/Median Mean/Median Mean/Median Mean/Median Mean/Median
NPH 19,674/3,228 2,455/1,587 16,570/3,240 8,191/6,840 −3,104/0 5,736/4,528 2,632/4,528
IG 22,861/3,457 2,857/1,959 19,746/3,143 10,818/9,343 −3,115/0 7,962/6,551 4,847/6,551
ID 9,544/2,458 3,041/1,608 11,402/2,647 12,351/10,706 1,858/0 9,310/7,690 11,168/7,690
PM 30,990/4,806 2,155/1,430 22,441/3,681 8,617/7,877 −8,549/-265 6,462/5,972 −2,087/5,707
p-values <0.0001 <0.0001 0.0001 <0.0001 0.0011 <0.0001
NPH Neutral protamine Hagedorn, IG insulin glargine, ID insulin determir, PM premixed insulin, SD standard deviation. The approximate value of 100 SEK is
currently 12 US dollars (August 2015)
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Discussion and conclusions
This observational study provides information on costs
of the use different types of insulin regimens in patients
with type 2 diabetes failing oral glucose-lowering treat-
ment. The results show that although the initiation of
insulin treatment generally entails increased diabetes-
related health care contacts and treatment costs, it also
generally results in a decrease in health care costs, espe-
cially when including costs for the treatment and care of
cardiovascular diseases. The median changes in costs
were generally smaller than the mean changes, reflect-
ing great variations between patients. The treatment
costs were higher for IG, ID and PM compared with
NPH, although history cardiovascular disease and dia-
betes complications as well as higher diabetes-related
and other treatment costs were independent predictors.
Overall, with respect to diabetes-related health care,
only PM (but not IG or ID) were associated with higher
costs, although these were also independently predicted
by cardiovascular morbidity and markers of compli-
cated diabetes.
There are generally differences in clinical characteristics
between the patients offered the various treatment options
when additional treatment is required on top of OHA in
clinical practice. Still, this project including previously
presented clinical results [10], provides arguments against
the use of PM due to weight gain, higher insulin doses,
rates of hypoglycaemia and diabetes–related health care
costs compared with the reference, treatment with NPH.
The treatment costs of IG and ID are higher than NPH,
but seem to offer other advantages, possibly such as ease
of use and low rates of hypoglycaemia, leading to similar
overall costs.
Other studies of the costs of initiating basal insulin
have reached similar conclusions. A retrospective study
on a U.S. population between 2001 and 2006 found that
IG compared with NPH had higher drug-related costs,
but no significant difference in health-care costs, al-
though both were associated with major cost reductions
[11]. Similarly, a UK retrospective primary care register
study with data from 1988–2010 found that insulin ana-
logues were associated with higher costs than NPH for
the first year but after three years [12]. Contrarily, a
Swiss simulation study found IG would be more cost-
effective than NPH in the long term [13]. A recent sys-
tematic review and meta-analysis concluded that long
acting insulin analogues are probably superior to NPH,
although the difference is small for HbA1c [14]. The
effects of treatment with premixed insulin have also
been evaluated [9, 15], leading to careful recommenda-
tions of its use [1, 2, 16].
The present study has several strengths. The observa-
tional design allows for comparisons of the effective-
ness and costs of different types of insulin, and the
results are likely to be representative of clinical practice
in countries with similar populations, following similar
Table 3 Costs (SEK) of health care and treatments (including cardiovascular costs) before and after starting the insulin treatment
Pre-index Post-index Increment Net cost
effectHealth care Treatment Health care Treatment Health care Treatment
Treatment Mean/Median Mean/Median Mean/Median Mean/Median Mean/Median Mean/Median Mean/Median
NPH 24,791/3,681 3,449/2,398 19,390/3,681 9,279/7,879 −5,401/0 5,831/4,659 430/4,659
IG 25,197/3,681 3,920/2,679 23,539/3,681 11,967/10,670 −1,658/0 8,047/6,569 6,389/6,569
ID 17,981/2,613 3,815/2,194 13,070/2,955 13,143/11,306 −4,912/0 9,328/7,808 4,416/7,808
PM 36,724/6,366 3,183/2,259 26,388/4,262 9,744/8,800 −10,336/-773 6,560/6,010 −3,776/5,237
p-values <0.0001 <0.0012 <0.0001 <0.0001 0.0022 <0.0001
NPH Neutral protamine Hagedorn, IG insulin glargine, ID insulin determir, PM premixed insulin, SD standard deviation. The approximate value of 100 SEK is
currently 12 US dollars (August 2015)
Table 4 Other costs before and after starting the insulin treatment
Pre-index Post-index Increment Net cost
effectHealth care Treatment Health care Treatment Health care Treatment
Treatment Mean/Median Mean/Median Mean/Median Mean/Median Mean/Median Mean/Median Mean/Median
NPH 25,417/9,215 5,209/2,445 24,173/10,439 6,287/2,926 −1,244/755 1,078/125 −166/880
IG 23,533/10,341 5,576/2,784 28,096/12,447 7,063/3,267 4,563/1,225 1,486/224 6,049/1,449
ID 20,297/9,205 4,515/1,455 22,313/10,652 5,300/1,819 2,016/1,717 785/160 2,801/1,877
PM 28,423/10,752 6,380/3,150 26,880/12,191 7,549/3,877 −1,543/883 1,169/283 −374/1,166
p-values 0.0054 <0.00001 0.0010 <0.00001 0.55 0.052
NPH Neutral protamine Hagedorn, IG insulin glargine, ID insulin determir, PM premixed insulin, SD standard deviation. The approximate value of 100 SEK is
currently 12 US dollars (August 2015)
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treatment guidelines [17]. All patients fulfilling the inclu-
sion criteria have been included in the calculations, which
are based on detailed information from administrative
systems with complete coverage. Apart from the general
limitations characteristic of observational studies, one
weakness in the present study was the limited number of
patients on IG and ID, particularly the latter. The lack of
reliable data on non-severe hypoglycaemia (i.e., not requir-
ing hospitalization), or patient-reported measures, are
important limitations. Furthermore, Analyses did not pro-
vide a societal perspective, since neither sick-leave informa-
tion (productivity gains and losses), nor direct non-medical
costs, were considered [18].
This study demonstrates that the initiation of insulin
in patients with type 2 diabetes in clinical practice leads
to increased health care contacts, overall and treatment
costs, but also generally results in a decrease in health
care costs. The diabetes-related treatment cost was low-
est using NPH insulin but only premixed insulin was
associated with higher diabetes-related health care costs
than NPH.
Additional file
Additional file 1: Table S1. Potential predictors of diabetes-related
health care contacts. Table S2. Potential predictors of diabetes-related
health care costs. Table S3. Potential predictors of diabetes-related treat-
ment costs. (DOCX 29 kb)
Competing interests
B. Eliasson has participated in advisory boards for Sanofi, Eli Lilly and Novo
Nordisk and served as a lecturer at educational meetings arranged by these
companies. V. Lak, M. Pirouzi Fard and A.M. Svensson declare no conflicts of
interest.
Authors’ contributions
AMS, MNPF and BE contributed to the conception and design of the study.
AMS and MNPF acquired data, and did the statistical analyses. BE and VL
drafted the report, and AMS, VL and BE critically revised and finalised it. All
authors read and approved the final manuscript.
Author details
1Center of Registers in Region Västra Götaland, Göteborg, Sweden.
2Department of Medicine, Sahlgrenska University Hospital, University of
Gothenburg, S-413 45 Göteborg, Sweden.
Received: 17 August 2015 Accepted: 28 October 2015
References
1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M,
et al. Management of hyperglycaemia in type 2 diabetes: a patient-
centered approach. Position statement of the American Diabetes
Association (ADA) and the European Association for the Study of
Diabetes (EASD). Diabetologia. 2012;55:1577–96.
2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al.
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered
approach: update to a position statement of the American Diabetes Association
and the European Association for the Study of Diabetes. Diabetes Care.
2015;38(1):140–9.
3. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2
diabetes mellitus: scientific review. JAMA. 2003;289(17):2254–64.
4. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-
acting insulin analogues versus NPH insulin (human isophane insulin) for type 2
diabetes mellitus. Cochrane Database Syst Rev. 2007;2, CD005613.
5. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of
insulin analogues for the management of diabetes mellitus: a meta-analysis.
CMAJ. 2009;180(4):385–97.
6. Eliasson B, Ekström N, Bruce Wirta S, Odén A, Pirouzi Fard M, Svensson A-M.
Metabolic effects of basal or premixed insulin treatment in 5077 insulin-
naïve type 2 diabetes patients: registry-based observational study in clinical
practice. Diabetes Therapy. 2014:in press.
7. Meyers JL, Parasuraman S, Bell KF, Graham JP, Candrilli SD. The high-cost,
type 2 diabetes mellitus patient: an analysis of managed care administrative
data. Arch Public Health. 2014;72(1):6.
8. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes
mellitus. CMAJ. 2009;180(4):400–7.
9. Baser O, Tangirala K, Wei W, Xie L. Real-world outcomes of initiating insulin
glargine-based treatment versus premixed analog insulins among US patients
with type 2 diabetes failing oral antidiabetic drugs. Clinicoecon Outcomes Res.
2013;5:497–505.
10. Eliasson B, Ekstrom N, Bruce Wirta S, Oden A, Fard MP, Svensson AM.
Metabolic effects of Basal or premixed insulin treatment in 5077 insulin-
naive type 2 diabetes patients: registry-based observational study in clinical
practice. Diabetes Ther. 2014;5(1):243–54.
11. Lee LJ, Yu AP, Johnson SJ, Birnbaum HG, Atanasov P, Buesching DP, et al.
Direct costs associated with initiating NPH insulin versus glargine in patients
with type 2 diabetes: a retrospective database analysis. Diabetes Res Clin
Pract. 2010;87(1):108–16.
12. Idris I, Gordon J, Tilling C, Vora J. A cost comparison of long-acting insulin
analogs vs NPH insulin-based treatment in patients with type 2 diabetes
using routinely collected primary care data from the UK. J Med Econ.
2015;18(4):273–82.
13. Brandle M, Azoulay M, Greiner RA. Cost-effectiveness of insulin glargine
versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling
the interaction between hypoglycemia and glycemic control in Switzerland.
Int J Clin Pharmacol Ther. 2011;49(3):217–30.
14. Tricco AC, Ashoor HM, Antony J, Beyene J, Veroniki AA, Isaranuwatchai W,
et al. Safety, effectiveness, and cost effectiveness of long acting versus
intermediate acting insulin for patients with type 1 diabetes: systematic
review and network meta-analysis. BMJ. 2014;349:g5459.
15. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al. Addition
of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl
J Med. 2007;357(17):1716–30.
16. Mosenzon O, Raz I. Intensification of insulin therapy for type 2 diabetic
patients in primary care: basal-bolus regimen versus premix insulin analogs:
when and for whom? Diabetes Care. 2013;36 Suppl 2:S212–8.
17. Force IDFCGT. Global Guideline for Type 2 Diabetes: recommendations for
standard, comprehensive, and minimal care. Diabet Med. 2006;23(6):579–93.
18. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health
and Medicine. New York: Oxford University Press; 1996.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Svensson et al. Clinical Diabetes and Endocrinology  (2015) 1:17 Page 6 of 6
